Cutaneous manifestations of anti-angiogenic therapy in oncology: Review with focus on VEGF inhibitors

Ishak, Rim; Aad, Simon Abi; Kyei, Angela; Farhat, Fadi

doi:10.1016/j.critrevonc.2013.11.007

Cited by 50 publications

(39 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both transient and sustained elevations of the intra-orbital pressure have been observed in these patients following anti-VEGF therapy [9,40]. Serious adverse effects, such as malignant hypertension and cutaneous, renal, hepatic and hematological toxicities, have also been reported in cancer patients receiving anti-angiogenic therapies [41]. Accordingly, the high cost and serious toxicities of the presently used anti-angiogenic drugs have prompted a search of alternative strategies.…”

Section: Currently Used Anti-angiogenesis Agentsmentioning

confidence: 99%

Plants and their active compounds: natural molecules to target angiogenesis

Bhat

Basu

2016

Angiogenesis

View full text Add to dashboard Cite

Angiogenesis, or new blood vessel formation, is an important process in the pathogenesis of several diseases and thus has been targeted for the prevention and treatment of many disorders. However, the anti-angiogenic agents that are currently in use are mainly synthetic compounds and humanized monoclonal antibodies, which are either expensive or toxic, thereby limiting their use in many patients. Therefore, it is necessary to identify less toxic, inexpensive, novel and effective anti-angiogenic molecules. Several studies have indicated that natural plant products can meet these criteria. In this review, we discuss the anti-angiogenic properties of natural compounds isolated from plants and the molecular mechanisms by which these molecules act. Finally, we summarize the advantages of using plant products as anti-angiogenic agents. Compared with currently available anti-angiogenic drugs, plant products may not only have similar therapeutic potential but are also inexpensive, less toxic and easy to administer. However, novel and effective strategies are necessary to improve their bioavailability for clinical use.

show abstract

Section: Currently Used Anti-angiogenesis Agentsmentioning

confidence: 99%

Plants and their active compounds: natural molecules to target angiogenesis

Bhat

Basu

2016

Angiogenesis

View full text Add to dashboard Cite

show abstract

“…VEGF is a family of growth factors that belongs to the platelet-derived growth factor (PDGF) superfamily and consists of several glycoproteins designated as VEGF-A, -B, -C, -D and -E, and the placenta growth factor (PlGF). VEGF-A, normally referred to simply as VEGF, is a dimeric glycoprotein of 34-45 kDa that promotes angiogenesis by inducing proliferation, differentiation and migration of vascular endothelial cells (Ishak et al, 2013). …”

Section: Introductionmentioning

confidence: 99%

Vascular endothelial growth factor immunoexpression is increased in malignant salivary gland tumors

Fonseca

Basso

Mariano

et al. 2015

Annals of Diagnostic Pathology

View full text Add to dashboard Cite

show abstract

“…pancreatic carcinoma, breast cancer, prostate cancer, lung cancer, and melanoma [14][15][16]. All these results make VEGF a target for many angiogenesis inhibitors and of keen interest in the field of cancer research [17]. In our prior research, several 16,17-pyrazoannulated steroids were synthesized and proved to exhibit potent VEGF inhibitory activity.…”

Section: Introductionmentioning

confidence: 96%